Michael A Koldobskiy
Overview
Explore the profile of Michael A Koldobskiy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1086
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liapodimitri A, Tetens A, Craig-Schwartz J, Lunsford K, Skalitzky K, Koldobskiy M
Cancers (Basel)
. 2025 Jan;
16(24.
PMID: 39766049
Among the most significant discoveries from cancer genomics efforts has been the critical role of epigenetic dysregulation in cancer development and progression. Studies across diverse cancer types have revealed frequent...
2.
Hilgart E, Zhou W, Martinez-Montes E, Idrizi A, Tryggvadottir R, Gondek L, et al.
bioRxiv
. 2024 Nov;
PMID: 39554147
Disruption of the epigenetic landscape is of particular interest in acute myeloid leukemia (AML) due to its relatively low mutational burden and frequent occurrence of mutations in epigenetic regulators. Here,...
3.
Kohnke T, Karigane D, Hilgart E, Fan A, Kayamori K, Miyauchi M, et al.
bioRxiv
. 2024 Nov;
PMID: 39553934
Genetic mutations are being thoroughly mapped in human cancers, yet a fundamental question in cancer biology is whether such mutations are functionally required for cancer initiation, maintenance of established cancer,...
4.
Tetens A, Martin A, Arnold A, Novak O, Idrizi A, Tryggvadottir R, et al.
Neurooncol Adv
. 2024 Mar;
6(1):vdae023.
PMID: 38468866
Background: Diffuse intrinsic pontine glioma (DIPG) is a uniformly lethal brainstem tumor of childhood, driven by histone H3 K27M mutation and resultant epigenetic dysregulation. Epigenomic analyses of DIPG have shown...
5.
Koschmann C, Al-Holou W, Alonso M, Anastas J, Bandopadhayay P, Barron T, et al.
Cancer Cell
. 2023 Dec;
42(1):1-5.
PMID: 38039965
Recent clinical trials for H3K27-altered diffuse midline gliomas (DMGs) have shown much promise. We present a consensus roadmap and identify three major barriers: (1) refinement of experimental models to include...
6.
Fang Y, Ji Z, Zhou W, Abante J, Koldobskiy M, Ji H, et al.
Nucleic Acids Res
. 2023 Feb;
51(5):2046-2065.
PMID: 36762477
Epigenetic information defines tissue identity and is largely inherited in development through DNA methylation. While studied mostly for mean differences, methylation also encodes stochastic change, defined as entropy in information...
7.
Ktena Y, Koldobskiy M, Barbato M, Fu H, Luznik L, Llosa N, et al.
J Clin Invest
. 2022 May;
132(13).
PMID: 35608905
DNA methyltransferase 3a (DNMT3a) is an important part of the epigenetic machinery that stabilizes patterns of activated T cell responses. We hypothesized that donor T cell DNMT3a regulates alloreactivity after...
8.
Christodoulou I, Ho W, Marple A, Ravich J, Tam A, Rahnama R, et al.
J Immunother Cancer
. 2021 Dec;
9(12).
PMID: 34896980
Background: The prognosis of patients with recurrent/refractory acute myelogenous leukemia (AML) remains poor and cell-based immunotherapies hold promise to improve outcomes. Natural Killer (NK) cells can elicit an antileukemic response...
9.
Koldobskiy M, Jenkinson G, Abante J, Rodriguez DiBlasi V, Zhou W, Pujadas E, et al.
Nat Biomed Eng
. 2021 Apr;
5(4):360-376.
PMID: 33859388
In cancer, linking epigenetic alterations to drivers of transformation has been difficult, in part because DNA methylation analyses must capture epigenetic variability, which is central to tumour heterogeneity and tumour...
10.
Rao F, Cha J, Xu J, Xu R, Vandiver M, Tyagi R, et al.
Mol Cell
. 2020 Aug;
79(4):702.
PMID: 32822581
No abstract available.